Sunshine Biopharma Warrant Stock Fundamentals
| SBFMW Stock | USD 0.12 0.03 29.89% |
Sunshine Biopharma Warrant fundamentals help investors to digest information that contributes to Sunshine Biopharma's financial success or failures. It also enables traders to predict the movement of Sunshine Stock. The fundamental analysis module provides a way to measure Sunshine Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sunshine Biopharma stock.
At this time, Sunshine Biopharma's Gross Profit is fairly stable compared to the past year. Net Interest Income is likely to climb to about 632.4 K in 2024, despite the fact that EBIT is likely to grow to (4.5 M). Sunshine | Select Account or Indicator |
Sunshine Biopharma Warrant Company Return On Equity Analysis
Sunshine Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sunshine Biopharma Return On Equity | -0.18 |
Most of Sunshine Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sunshine Biopharma Warrant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Sunshine Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Sunshine Biopharma Warrant has a Return On Equity of -0.1848. This is 99.23% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 40.39% lower than that of the firm.
Sunshine Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sunshine Biopharma's current stock value. Our valuation model uses many indicators to compare Sunshine Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sunshine Biopharma competition to find correlations between indicators driving Sunshine Biopharma's intrinsic value. More Info.Sunshine Biopharma Warrant is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At this time, Sunshine Biopharma's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sunshine Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Sunshine Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sunshine Biopharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sunshine Biopharma could also be used in its relative valuation, which is a method of valuing Sunshine Biopharma by comparing valuation metrics of similar companies.Sunshine Biopharma is currently under evaluation in return on equity category among its peers.
Sunshine Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0914 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.18) % | ||||
| Number Of Shares Shorted | 3.09 K | ||||
| Revenue | 24.09 M | ||||
| Gross Profit | 110.6 K | ||||
| EBITDA | (4.64 M) | ||||
| Net Income | (4.51 M) | ||||
| Cash And Equivalents | 40.56 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 657.71 K | ||||
| Debt To Equity | 8.98 % | ||||
| Current Ratio | 85.09 X | ||||
| Book Value Per Share | 24.94 X | ||||
| Cash Flow From Operations | (8.78 M) | ||||
| Earnings Per Share | (2.21) X | ||||
| Number Of Employees | 44 | ||||
| Beta | -0.78 | ||||
| Total Asset | 27.35 M | ||||
| Retained Earnings | (63.91 M) | ||||
| Working Capital | 19.34 M | ||||
| Net Asset | 27.35 M |
About Sunshine Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sunshine Biopharma Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunshine Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunshine Biopharma Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 344.8 K | 192.1 K | |
| Total Revenue | 24.1 M | 25.3 M | |
| Cost Of Revenue | 15.9 M | 16.7 M | |
| Stock Based Compensation To Revenue | 4.62 | 6.27 | |
| Sales General And Administrative To Revenue | 0.42 | 0.40 | |
| Research And Ddevelopement To Revenue | 0.08 | 0.07 | |
| Capex To Revenue | (0.03) | (0.03) | |
| Revenue Per Share | 99.02 | 103.97 | |
| Ebit Per Revenue | (0.20) | (0.21) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| COST | Costco Wholesale Corp | |
| AMZN | Amazon Inc | |
| AVGO | Broadcom |
Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.